0000358654
Donate

Reimbursement status:
Reimbursement with restrictions

Cancer: Multiple myeloma and plasma cell neoplasms

Indication:

Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L04AX
L04AX Other immunosuppressants
EMA approval status :
Approved
EMA approval date :
2013-08-05
EMA conditional? :
No
EMA orphan? :
Yes
EMA biological? :
No